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While recent advances clarified the molecular and cellular modes of action of
antiarrhythmic drugs (AADs), their link to suppression of dynamical arrhythmia
mechanisms remains only partially understood. The current classifications of AADs
(Classes I, III, and IV) rely on blocking peak Na, K and L-type calcium currents (ICa,L),
with Class II with dominant beta receptor blocking activity and Class V including drugs
with diverse classes of actions. The discovery that the calcium and redox sensor, cardiac
Ca/calmodulin-dependent protein kinase II (CaMKII) enhances both the late Na (INa-L)
and the late ICa,L in patients at high risk of VT/VF provided a new and a rational AAD
target. Pathological rise of either or both of INa-L and late ICa,L are demonstrated to
promote cellular early afterdepolarizations (EADs) and EAD-mediated triggered activity
that can initiate VT/VF in remodeled hearts. Selective inhibition of the INa-L without
affecting their peak transients with the highly specific prototype drug, GS-967 suppresses
these EAD-mediated VT/VFs. As in the case of INa-L, selective inhibition of the late
ICa,L without affecting its peak with the prototype drug, roscovitine suppressed oxidative
EAD-mediated VT/VF. These findings indicate that specific blockers of the late inward
currents without affecting their peaks (gating modifiers), offer a new and effective AAD
class action i.e., “Class VI.” The development of safe drugs with selective Class VI actions
provides a rational and effective approach to treat VT/VF particularly in cardiac conditions
associated with enhanced CaMKII activity such as heart failure.
Keywords: late Na current, late Ca current, ventricular fibrillation, early afterdepolarization, triggered activity,
roscovitine, GS-458-967, antiarrhythmic drugs
A BRIEF HISTORICAL PERSPECTIVE OF ANTIARRHYTHMIC
DRUG (AAD) THERAPY
It may seem ironic that “antiarrhythmic” drug therapy long antedated the electrocardiographic
diagnosis of cardiac arrhythmias when the French physician Jean Baptist de Sénac first described
in 1749 the benefits of quinine in patients with “palpitations,” an implicit reference to atrial
fibrillation (AF).
“Of all the stomachic remedies the one whose effects appeared to be the most constant and the most prompt
in many cases is quinine, mixed with a little rhubarb. Long and rebellious palpitations have ceded to this
febrifuge seconded with a light purgative” (Willius and Keys, 1941).
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The Paris-based physician, who perhaps was the first to describe
in patients the correlation between palpitation (AF) and mitral
valve disease, did extensive research on the cinchona extract that
contains quinine/quinidine and the plant rhubarb that contains
anthraquinones (laxatives). Sénac however, did not know if the
fever reducing effect of quinine or the laxative effect of the
anthraquinones or their combination were responsible to halt
the presumed AF (Karagueuzian, 1995). Sénac’s dilemma was
apparently solved more than 150 years later thanks to a Dutch
merchant who had discovered for himself the value of quinine
against AF. The traveling merchant, who regularly took quinine
to prevent malaria during his trips to the West Indies suffered
from AF and was a patient of no less than the famed cardiologist
Wenckebach, who recalled the experience of his patient this way:
“In 1912, a patient presented himself in my office wishing to get
rid of his attacks of auricular fibrillation...On my telling him that I
could promise nothing, he told me that he knew how to get rid of his
attacks, as I did not believe him he promised to come back the next
morning with a regular pulse, and he did...I was greatly struck by
this fact, and afterward tried this sort of treatment on many cases of
auricular fibrillation. My success was disappointing, in that quinine
abolished auricular fibrillation in only a few cases, and these cases
only when the onset of this form was quite recent, never when it was
of several years’ duration” (Moe, 1970).
Frey in 1918 reported that the d-isomer of quinine, quinidine,
also found in cinchona bark, exerts more powerful effect against
AF than the l-isomer quinine (Moe, 1970). The empiricism in
AAD therapy continued through the thirties by the collaborating
team of anesthesiologists and cardiac surgeons during open
heart surgery. They discovered in 1936 that the application
of the local anesthetic agent, procaine, either at the epicardial
surface of the heart or by intravenous injections in patients
during cardiac surgery provided “protection” against VT/VF by
reducing “cardiac irritability” (Mautz, 1936). This success led to
the ultimate development of the longer and more potent acting
analog of procaine, procainamide with lesser central nervous
system toxicity. Encouraged by the results of the local anesthetic
procaine, intravenous lidocaine was introduced byHitchcock and
associates for the rapid conversion of VT to sinus rhythm in the
late fifties (Hitchcock and Keown, 1959). An early attempt to a
“mechanistic” approach to combat VT/VFwas reported byHarris
and Kokernot (1950). These authors suggested the presence of
a similarity between the ectopic rapid ventricular discharges in
dogs after coronary artery occlusion and the focal epileptogenic
discharges in the brain of patients with epilepsy:
“...Drugs that have proved effective in preventing focal
seizures might suppress ectopic ventricular discharges which
Abbreviations: APD, action potential duration; AAD, antiarrhythmic drug; AF,
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II; CPVT, catecholaminergic polymorphic ventricular tachycardia; CCB,
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accompany acute myocardial infarction” (Harris and Kokernot,
1950).
Using dilantin (diphenylhydantoin, or DPH), a drug with
demonstrated efficacy against epileptic seizures in humans,
these authors recorded a measure of success in dogs with
acute ischemic VT/VF by asserting that: “The excitability and
automaticity of cardiac tissues are markedly similar to the
changes produced in excitability and automaticity of nerve and
skeletal muscle” (Harris and Kokernot, 1950). However, others
have suggested that DPH’s direct actions on cardiac Purkinje
fibers (shortening of the APD, reducing spontaneous phase
4 depolarization and firing rate) “were sufficient to suggest
an explanation for it anti-arrhythmic effect on ventricular
arrhythmias in vivo” (Bigger et al., 1968). It is possible that
both central and direct actions of DPH may conspire to bring
about a measure of antiarrhythmic effect (Karagueuzian, 1995).
Currently DPH has very limited use against VT/VF (Bäckman
et al., 1989).
AAD CLASS ACTIONS: FROM HUGGINS
TO SINGH-VAUGHAN WILLIAMS TO
HARRISON TO SICILIAN GAMBIT AND
BACK
The first classification of AADs was made in 1949 by Huggins
and associates (Huggins et al., 1949). These authors grouped the
drugs into three categories based on the drugs’(1) local anesthetic
effect; (2) adrenolytic potency and (3) coronary artery relaxing
effects (Huggins et al., 1949). This first ever AAD classification,
surprisingly not acknowledged in any of the subsequent AAD
classifications, was the origin of all subsequent classifications.
These pioneering authors tested the efficacy of what they called
“three groups” of drugs against epinephrine-induced ventricular
fibrillation (VF) in chloroform anesthetized dogs (Huggins
et al., 1949). The “first group of agents” included the coronary
vasodilators (i.e., sodium nitrite, aminophylline, papaverine, and
quinacrine); “the second group” included drugs that decreased
myocardial excitability (local anesthetic action) such as procaine,
quinidine sulfate; and the “third group of agents” manifested
sympatholytic activity (i.e., beta blocking effect) such as priscol
and dibenamine (Huggins et al., 1949). When the vasodilator
group was found ineffective it was dropped from the list leaving
(1) the myocardial excitability depressants and (2) the beta
adrenergic receptor blockers.
With the introduction in the late 1940s of cellular
transmembrane action potential recordings with the glass
microelectrode technique from atrium and ventricle, Singh and
Vaughan Williams introduced a “third class” of AAD action
in 1970 when they discovered that d-sotalol’s antiarrhythmic
efficacy was independent of beta blocking effect. Instead they
attributed d-sotalol’s antiarrhythmic efficacy to the drug’s ability
to prolong cardiac cellular action potential duration (APD),
thus proposing a “third class” of AAD action: prolongation of
the APD (Singh and Vaughan Williams, 1970a). This proposal
was based on two additional observations. First, on shortened
APD during atrial fibrillation (AF) initiated by thyrotoxicosis
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and resolution of the AF with thyroidectomy associated with
prolonged APD (Vaughan Williams, 1970). Second, based on
the effects of amiodarone, initially introduced as an antianginal
agent (Charlier et al., 1968) and later as an AAD (Charlier
et al., 1969) by prolonging atrial and ventricular APD (Singh
and Vaughan Williams, 1970a,b). The similarities of d-sotalol
and amiodarone to thyroidectomy in suppressing arrhythmias
by prolonging the APD led these authors to conclude that the
“prolongation of the APD may be considered as a third type of
action reducing the probability of the arrhythmia” (Vaughan
Williams, 1970). However, an apparent dilemma was created
when it was discovered that both quinidine and procainamide,
two Class I myocardial depressant drugs, also prolong the APD
similar to Class III drugs like d-sotalol and amiodarone. These
authors however, asserted that the myocardial depressant effect
of excitability caused by Class I AADs emerges prior to the APD
prolongation, therefore attributing quinidine’s antiarrhythmic
efficacy solely to its myocardial depressant effect of excitability
rather than to its APD prolonging effect (Szekeres and Williams,
1962; Singh and Vaughan Williams, 1970a). However, the later
confirmation of significant directional differences of the effects
of Class I AADs on cellular APD necessitated their separations
into three “sub-classes” on the basis of their ability to prolong
(Class 1A action), shorten (Class 1B action), or have no effect
(Class 1C action) on the APD (Harrison, 1985; Table 1).
There are great deals of overlaps between drugs of different
classes (Charlier, 1970) making rigid categorizations of the
current AADs a difficult task. Moreover, the classification is
based on the effects of AADs on cardiac action potential
characteristics rather than on clinical arrhythmias. For example,
Class 1C drug effect indicates “reduction of peak Na current
(INa) and no change in APD” and says nothing about its
therapeutic value. In short, the classification provides a useful
conversational shorthand with no distinct clinical value. In fact,
the shortcomings of the AAD classification was recognized back
in 1970 by Singh and VaughanWilliams in their original proposal
of Class III AAD action:
“The effect of anti-arrhythmic agents on various parameters of
cardiac function in vitro and in vivo have made it possible to
classify the drugs into groups which do or do not have certain
clearly definable pharmacological actions though these actions do
not necessarily determine anti-arrhythmic effectiveness” (Singh and
Vaughan Williams, 1970a).
Class IV AADs The discovery of verapamil in the seventies, a Ca
channel blocker (CCB) (Kohlhardt et al., 1972), that exerts potent
AA efficacy against diverse experimental models of arrhythmias
including myocardial ischemia, A–V nodal reentrant tachycardia
and digitalis toxicity necessitated the introduction of CCB as a
fourth class (Class IV) of AAD action (Kohlhardt et al., 1972;
Rosen et al., 1975; Table 1), replacing the “centrally acting”
Class IV AADs (i.e., Dilantin) originally proposed by Vaughan
Williams (1970). Unfortunately, the concentrations of Class IV
AADs that suppress arrhythmias cause severe negative inotropic
effects that greatly diminish their therapeutic value, particularly
in patients with compromised cardiac function (Rosen et al.,
1975).
TABLE 1 | Updated classification of antiarrhythmic drugs.
Class I
IA Peak INa+ current
blockers
Quinidine, Procainamide, Disopyramide,
Cibenzoline
IB Lidocaine, Tocainide, Mexiletine,
Ethmozine, Ranolazine*
IC Encainide, Lorcainide, Flecainide,
Propafenone
Class II Beta blockers Propranolol, Esmolol, Timolol, Atenolol,
Metoprolol, Carvedilol
Class III K+ channel
blockers
Amiodarone, d-Sotalol, Ibutilide, Dofetilide,
Dronaderone
Class IV Ca2+ channel
blocker
Verapamil, Nifedipine, Diltiazem, Bepridil
Class V If blocker, and
other agents
Ivabradine, Adenosine, Digitalis,
Magnesium Sulfate
Class VI Late INa and late
ICa,L blockers
GS-458967 Roscovitine
* Given the structural similarity to lidocaine, ranolazine was initially grouped as Class 1B.
However, depending on the relative contributions of ranolazine’s block of IKr vs. INa-L the
APD may prolong (Class 1A), shorten (Class IB) or remain unchanged (Class 1C).
Class V AADs
Class V agents include molecules with diverse pharmacological
actions, including digitalis, adenosine, ivabradine, and
magnesium chloride. Some agents in this Class like vernakalant,
which blocks peak Na current and is effective against AF
(European Heart Rhythm et al., 2010), can be placed in several
classes, while others like ivabradine (sinus node pacemaker If
blocker), cannot be listed under any of the four classes (Thireau
et al., 2011). Same goes for digitalis that increases vagal activity
via its action on the central nervous system, thus decreasing the
conduction of electrical impulses through the AV node (van
Veldhuisen et al., 1996). As for adenosine, its actions are, for the
most part, due to the direct activation of the G protein-gated
inward rectifying potassium channels and antagonist of cAMP-
stimulated ion currents such as the pacemaker current and the
L type calcium current (ICa,L) (Lerman and Belardinelli, 1991;
Shryock and Belardinelli, 1997). The cardiac actions of adenosine
include slowing of sinus rate, depression of atrioventricular (AV)
nodal conduction, suppressing AV nodal reentrant tachycardia
(Belhassen et al., 1988; Camm and Garratt, 1994; Prystowsky
et al., 2015). Finally, MgCl2 is found effective against EAD-
mediated triggered activity in canine Purkinje fibers (Bailie et al.,
1988) and is suggested as a potential adjunctive therapy for
cardiac arrhythmias in humans (Baker, 2016).
THE SICILIAN GAMBIT “CLASSIFICATION”
The dissatisfaction with the current AAD classification systems
and the disappointing results with two major clinical trials,
the Cardiac Arrhythmia Suppression Trial (CAST) testing the
efficacy of Class I AADs (Echt et al., 1991) and the Survival With
Oral D-Sotalol (SWORD) clinical trial testing the efficacy of Class
III drug (Waldo et al., 1995) led a group of established cardiac
Frontiers in Pharmacology | www.frontiersin.org 3 February 2017 | Volume 8 | Article 36
Karagueuzian et al. Novel Class VI Antiarrhythmic Drug Action
electrophysiologists to propose supplementing the current AAD
class actions by incorporating the broad pharmacodynamic
actions of each AAD (Task force of the working group on
arrhythmias of the European Society on C, 1991). While
informative, this new approach, known as the Sicilian Gambit,
was argued to be “essentially similar” to the original classification
(Vaughan Williams, 1992). Indeed, and two decades later
members of the Group of the Sicilian Gambit Investigators, had
this to say:
“The Sicilian Gambit... was not meant in aggregating drugs
into categories, instead it was intended to provide background
information so to challenge thought and investigation rather than
to resolve issues” (Rosen and Janse, 2010).
The AAD therapy remains largely empirical. The link between
specific ionic effect(s) of a drug and suppression of a specific
arrhythmia mechanism(s) remain(s) incompletely understood
(Weiss et al., 2015). All AADs block with differing degrees
of potencies, multiple ionic currents that prevent precise
understanding as to which specific drug-induced ionic change(s)
in the heart is or are responsible for the outcome. The lack
of mechanistic understanding of the success or failure with
AAD therapy, greatly diminished the enthusiasm in innovative
AAD research. At the present there are important gaps in our
understanding of the ionic mechanism(s) of the arrhythmia
sought for therapy. As articulated by van Hamel:
“Manifestations of an arrhythmogenic substrate and its triggers
can be almost completely suppressed for a while -in clinical
terms defined as a therapeutic success and therefore satisfying-
without understanding in detail its mechanisms, anatomical extent,
natural course and potential complications. This attitude toward
arrhythmia management offers only short-term solutions and still
worse, suppresses our intellectual curiosity” (van Hamel, 2003).
Indeed, it is clear that better understanding of the molecular
pathological mechanisms of the arrhythmia would result in
a better and more effective management of the arrhythmia
because of possibility of specific drug targeting of the pathological
mechanisms of the arrhythmia. Unfortunately, at the present
there remain important gaps concerning the comprehension of
these mechanisms preventing a rational and specifically targeted
drug therapy of these arrhythmias.
The recent recognition of the pathological increases in the
late Na current (INa-L) and ICa,L as “vulnerable parameters”
for early afterdepolarizations (EADs)-mediated VT/VF provides
an opportunity to specifically target the dynamical arrhythmia
mechanism. Importantly, the suppression of these VT/VFs with
specific prototype blockers of INa-L and the late ICa,L without
affecting their peaks, provide a rational and effective AAD
therapy that specifically target the arrhythmiamechanism. Under
normal conditions, voltage-gated sodium channels (NaV1.5)
open suddenly upon depolarization permitting entry of Na+
that peaks in ≈1 ms (INa) then rapidly decays to baseline
as most Na+ channels quickly close (inactivate) during the
plateau phase of the action potential (AP). While a very small
persistent INa current may be present under normal conditions,
however, under diseased conditions INa inactivation can be
greatly slowed, independent of its peak, providing persistent
late Na current during the plateau phase of the AP three to
tenfold over the level of normal conditions (Belardinelli et al.,
2015). It is difficult to have a precise idea in absolute terms
the level at which INa-L increases as this level is profoundly
affected by diverse factors including differences in the clamp
protocol, species use, age (neonatal vs. adult), temperature (room
vs. body temperature), nature of the stress (i.e., heart failure,
ATX, hydrogen peroxide, toxins like aconitine). Importantly the
level of the INa-L depends on the timing when the “late” INa
is measured, 50 or 100 ms after the clamp pulse or during the
steady state (Ward and Giles, 1997; Song et al., 2006; Maltsev and
Undrovinas, 2008; Undrovinas and Maltsev, 2008; Antzelevitch
et al., 2014; Belardinelli et al., 2015; Wagner et al., 2015). It is
estimated that during the steady-state pathological increases of
the INa-L can reach up to 20-fold (roughly about 100 pA) of
control as shown in Figure 1D. Similarly as in the case of the
INa, the ICa,L inactivation rate can also be considerably slowed
under diverse cardiac conditions secondary to CaMKII activation
generating an enhanced late inward depolarizing current. This
ICa.L component, particularly relevant during the plateau and the
repolarization phases of the cardiac AP, became known as the
late ICa,L (Madhvani et al., 2015; Markandeya and Kamp, 2015).
Under normal conditions late ICa,L is minimal however, under
pathological conditions its amplitude increases significantly. As
in the case of the INa-L the absolute values of the late ICa-L
varies greatly due to the same factors mentioned for INa-L plus
the rundown phenomenon that is associated with the LCCs
(Yue et al., 1990; Xie et al., 2009; Madhvani et al., 2011, 2015;
Kim et al., 2016). Figures 2A,B shows variations in the absolute
amplitude of the late ICa-L depending on the conditions of the
study. Diverse acquired and congenital cardiac conditions at
risk of developing VT/VF including heart failure, myocardial
infarction and cardiomyopathies manifest pathological rises in
these late inward currents, often exacerbated by activation of
CaMKII signaling (Maltsev et al., 2007; Mollova et al., 2015).
In the ensuing sections, animal and human models of VT/VF
in which CaMKII activation plays a key role are presented.
Electrophysiological studies scaling from isolated myocytes to
intact hearts show that downstream increases in the INa-L and late
ICa,L play key roles in CaMKII-drivenVT/VF providing a rational
and effective AAD class action not considered in previous AAD
classifications.
ENHANCEMENT OF INA-L AND LATE ICA,L
VIA CAMKII SIGNALING
Evidence accumulated over the last two decades has provided
novel mechanistic insights into the ionicmechanisms of triggered
VT/VF that can be specifically targeted by small drug molecules.
The multifunctional and ubiquitous enzyme CaMKII is a
well demonstrated sensor of calcium and redox signaling that
enhances the INa-L and late ICa,L and plays a key role in
the pathogenesis of heart failure and arrhythmias both in
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FIGURE 1 | Enhanced INa-L, initiation of EADs and their selective suppression with specific INa-L blockers (A) shows increased INa-L induced with ATXII in
isolated guinea-pig ventricular myocyte initiating EADs and triggered activity (B) (From Isenberg and Ravens, 1984). (C) Shows absence of effect of the selective INa-L
blocker, GS-967 on peak INa induced with ATXII in isolated rabbit ventricular myocyte while selectively inhibiting the INa-L (D). (From Belardinelli et al., 2013) (E) Shows
50% reduction of peak INa in WT and (F) in LQT3 mutant Na channel (1KPQ) in HEK cells with sub-therapeutic (0.1 µM) concentrations of flecainide while also
causing non-specific reduction in the INa−L, (insets) (From Nagatomo et al., 2000). (G) Shows mexiletine’s concentration-dependent reduction of the peak INa in
isolated rabbit ventricular myocytes with no specific inhibitory effect on the INa-L (From Gao et al., 2013).
humans and in animal disease models (Erickson et al., 2008;
Xie et al., 2009; Belardinelli et al., 2015; Hund and Mohler,
2015; Pezhouman et al., 2015; Mustroph et al., 2016). Patients
with heart failure, hypertrophy and cardiomyopathies manifest
sustained hyperactivity of CaMKII (Erickson et al., 2008, 2011;
Mollova et al., 2015) promoting VT/VF (Swaminathan et al.,
2012; Luczak and Anderson, 2014). Isolated myocytes studies
have shown that CaMKII activation enhances the INa-L and the
late ICa,L(Xie et al., 2009; Belardinelli et al., 2015) promoting
EADs and triggered arrhythmias (Morotti et al., 2014; Foteinou
et al., 2015; Pezhouman et al., 2015). Consistent with these
findings, transgenic CaMKII overexpression in the mouse leads
to development of heart failure, while CaMKII deletion prevents
onset of heart failure following transaortic constriction (Maier
et al., 2003; Zhang et al., 2003; Backs et al., 2009; Ling et al.,
2009). CaMKII-based therapy of cardiac arrhythmias however,
is inherently difficult due to its vast signaling network requiring
a careful balance between the therapeutic benefit and the
potential off-target effects (e.g., neuronal or metabolic; Hund
and Mohler, 2015). An alternative would be specific down-
stream targets of the CaMKII pathway known to play key role
in promoting arrhythmias. The INa-L and the late ICa,L are
two demonstrated down-stream targets that play a key role
in EAD-mediated arrhythmias (Morita et al., 2011a; Madhvani
et al., 2015). Indeed, dynamic-clamp and simulation studies have
shown that selective enhancement of the late ICa,L or the INa-L
without changing any other ionic currents is sufficient to promote
EADs and triggered activity (Madhvani et al., 2011, 2015). These
findings indicate that the other downstream effects of CaMKII
activation including, phosphorylation of ryanodine receptor,
(RyR2), phospholamban (PLB), sarco/plasmic-endoplasmic Ca-
activated ATPase type 2a (SERCA2a), and increased Na-Ca
exchanger current (INCX) (Marx et al., 2000; Hund and Mohler,
2015; Mustroph et al., 2016), while potentially modulating the
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FIGURE 2 | Enhanced late ICa,L and its selective block with roscovitine but not with verapamil. (A–C) show the time course of the peak and the pedestal
(ped) ICa,L during a 300-ms voltage clamp pulse to 0 mV (voltage protocol shown in B). (B). Voltage clamp pulse (above) and superimposed current traces showing
ICa,L before (black) and ∼5 min after perfusion of 1 mmol/L H2O2 (red). The difference current is shown in the bottom trace. (C), Same as in (B) but with an AP clamp
waveform replacing the square voltage clamp pulse (From Xie et al., 2009). (D) Shows an iPSC-derived cardiomyocyte from a patient with TS showing increased late
ICa,L (From Yazawa et al., 2011). (E) Shows selective block of the late ICa,L with roscovitine in a cardiomyocyte derived form a TS patient without affecting the peak
ICa,L (From Yazawa et al., 2011). (F) Shows lack of selective block of the late ICa,L with verapamil while causing severe depression of the peak ICa,L (From Nawrath
et al., 1998).
genesis of EADs do not appear necessary for oxidative EAD
formation in isolated ventricular myocytes (Madhvani et al.,
2011, 2015) and EAD-mediated VT/VF in intact hearts (Morita
et al., 2011a; Pezhouman et al., 2016). The Ca handling proteins
however, could play an important role both in atrial and
ventricular tissue in promoting DAD-mediated fibrillation as
shown in human and animal studies (Voigt et al., 2012; Luczak
and Anderson, 2014).
The Late Na Current (INa-L)
The pathological rise of the late Na current known as late
INa (INa-L), emerges under cardiac conditions associated with
increased risk of developing VT/VF(Belardinelli et al., 2015)
secondary to the activation of CaMKII signaling pathway
(Erickson et al., 2011) andmutations of Nav1.5 channels (Bennett
et al., 1995; Ulbricht, 2005). The cardiac conditions associated
with increased risk of VT/VF include human congenital
LQT3 (Bennett et al., 1995; Ulbricht, 2005) and laminopathy
(Markandeya et al., 2016) and a host of acquired chronic cardiac
diseases including heart failure (Maltsev et al., 2007), myocardial
ischemia (Belardinelli et al., 2013), increased pro-oxidant states
(Ward and Giles, 1997; Song et al., 2006; Xie et al., 2009), and
hypertrophic cardiomyopathy (Coppini et al., 2013; Belardinelli
et al., 2015). It howevermust be emphasized that in the congenital
LQT3, the INa-L is not necessarily CaMKII-dependent. The
importance of pathological rise of the INa-L in the genesis of
EADs and EAD-mediated arrhythmia has been systematically
studied in isolated cardiac myocytes using potent toxins like
sea anemone toxin II (ATX-II) that specifically enhance the
INa-L with minimal effect on other ionic currents (Isenberg and
Ravens, 1984; Belardinelli et al., 2015; Figures 1A,B). The key
role played by the selective increase of the INa-L current in
EAD-mediated arrhythmias is demonstrated using the highly
selective and potent (IC50 of 134 nM) blocker of the INa-L,
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GS-458967 (GS-967) (Belardinelli et al., 2013) in suppressing
INa-L as shown in Figures 1C,D). This selective effect of GS-967
on INa-L is fundamentally different from the traditional Class 1
AADs like flecainide and mexiletine that potently block the peak
INa as shown in Figures 1E–G. The demonstrated efficacy of GS-
967 to suppress EAD-mediated arrhythmias provided a direct
link between a specific molecular action of a drug (i.e., “gating
modifier” specific block of INa-L) and a dynamical arrhythmia
mechanism (enhanced INa-L-mediated EADs) (Qu et al., 2013).
The term “gating modifier” has been used to refer to the
mode of action of toxins that alter the voltage dependence of
voltage gated ion channels by binding to structures that undergo
conformational changes during gating, e.g., the voltage sensing
domains (Catterall et al., 2007; Kalia et al., 2015). Here, we used
the term gating modifier to refer to drug action that alter channel
opening and channel closing without directly blocking the pore.
Modulation of the gating of brain sodium channels accounts,
at least in part, for the ability of several anti-epileptic drugs
including lamotrigine to suppress epileptic attacks. Interestingly
it is shown that lamotrigine exerts its effect by binding to the
two voltage sensors, segments S4, of the domains III and IV
of Nav channel that potently suppress EAD-mediated triggered
activity (epileptic discharges) without affecting ordinary nerve
action potential firing (Rogawski and Loscher, 2004). This finding
suggest that the voltage sensor domain of the voltage gated Na
channels can be a drugable target for antiepileptic drugs. Indeed,
in a transgenic mousemodel of epilepsy (Scn2aQ54), the INa-L was
found to be increased significantly from 1 to 3 percent of peak
INa and importantly the specific INa-L blocker prototype GS-967,
mitigated epileptic attacks (Anderson et al., 2014). These findings
suggest that the gating modifiers of Nav channels may be effective
and target specific anti-epileptics (Anderson et al., 2014; George,
2015).
Unfortunately, the current Classes of AADs are incapable to
selectively discriminate between the pathological INa-L and the
normal peak INa necessary for normal AP upstroke velocity as
they equally suppress both the early and late components of the
INa. For example, flecainide (Class 1C AAD) blocks both the peak
INa and INa-L in wild type and in LQT3 mutant Na channels as
shown in Figures 1E,F. Similarly, mexiletine, a Class 1B AAD
has similar effects as flecainide on peak and INa-L (Figure 1G;
Gao et al., 2013). The partially selective INa-L blocker ranolazine,
while suppressing the INa-L and EAD-mediated VT/VF (Sicouri
et al., 2008; Morita et al., 2011a) was tentatively suggested to fit
Class 1B, due to its structural similarity to lidocaine (Thireau
et al., 2011). However, ranolazine blockade of IKr which tends to
prolong the APD and the QT interval may well place it in the
Class IA category, like quinidine (Table 1).
The Late L-Type Ca Current (ICa,L)
Cardiac conditions that increase the late ICa,L are invariably
associated with increased risk of VT/VF, including heart failure
(Mewes and Ravens, 1994; Cooper et al., 2010), congenital LQT8
mutations and Timothy Syndrome (TS) (Figure 2A; Limpitikul
et al., 2014; Marsman et al., 2014; Dick et al., 2016) increased pro-
oxidant states, (Figure 2B; Xie et al., 2009) aging, (Zhou et al.,
1998; Salameh et al., 2010), and Duchenne muscular dystrophy
(Koenig et al., 2011; Viola et al., 2013) and in stem cell derived
FIGURE 3 | Late ICa,L antiarrhythmic modifications. Class IV antiarrhythmics block the L-type channels indiscriminately reducing peak and late ICa,L, suppressing
EC-coupling. ICa,L gating modifications identified by dynamic clamp studies (Madhvani et al., 2011, 2015) specifically reduce late ICa,L, potently abolishing EADs
without affecting maximum Cav1.2 open probability; therefore peak ICa,L remains largely preserved. These maneuvers include: (1) pedestal reduction from 10 to 4%;
(2) a 5 mV depolarizing shift of steady-state activation; (3) a 5 mV hyperpolarizing shift of SS-inactivation. Roscovitine enantiomers can reduce late ICa,L (pedestal).
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cardiomyocytes from patients with Timothy syndrome (Yazawa
et al., 2011; Figure 2D).
Electrophysiological studies in isolated cardiac myocytes have
shown that an increase in the late ICa,L causes EADs (Xie
et al., 2009; Figure 2C). Most EADs develop between −40 and
0 mV, a range of membrane potentials commonly referred to
as the window current region, where the steady-state activation
and steady-state inactivation curves overlap. Within the ICa,L
window region, a fraction of Ca channels are not fully inactivated
maintaining a non-zero open probability responsible for the
late Ca current. Recent studies based on dynamic clamp data
provide compelling evidence that interventions reducing late
ICa,L by either by (1) shifting the ICa,L steady-state activation in
the depolarizing direction by <5mV, (2) shifting the steady-state
inactivation curve in the hyperpolarizing direction by (<5
mV), or (3) reducing the non-inactivating (pedestal) component
(Madhvani et al., 2015; Figure 3) potently suppresses EADs and
therefore carry a strong therapeutic value for suppressing EAD-
mediated VT/VF. Traditional CCBs like verapamil or nifedipine
can suppress oxidative EADs by blocking ICa,L (Xie et al., 2009)
however, their suppressant effect of EADs comes at a cost of
considerable reduction of the peak ICa,L as shown in Figure 2E.
The simultaneous block of peak and late ICa,L by a drug
greatly diminishes the therapeutic value particularly in patients
with compromised cardiac function (Figure 2F; Nawrath et al.,
1998). Importantly, the dynamic clamp studies of Madhvani
et al. (2015) provide compelling evidence that the blockade
of peak ICa,L is not only undesirable but also not necessary
for EADs suppression! These studies made it clear that the
selective reduction of the late ICa,L can preserve Ca transient and
FIGURE 4 | Oxidative stress with angiotensin II (ANG II) induces early afterdepolarizations (EADs), VT/VF in an aged but not young rat hearts. In all
(A–C), simultaneous microelectrode (ME) and pseudo-ECG recordings in a young heart (A) and an aged heart (B,C) exposed to ANG II (2 mol/l). A: representative
experiment in a young heart showing that sinus rhythm persists throughout 60min of ANG II perfusion. (B,C) Recordings from an aged heart showing the emergence
of EADs, triggered activity, and VF over the indicated time course. (D) Three isochronal activation maps, with the first being the last sinus beat (beat 1) before the
onset of the VF shown at the bottom and indicated as 1 in the ECG (bottom). The sinus beat was followed by two consecutive focal activations that arose from the
base of the heart (beats 2 and 3). The red arrows in (D) indicate the direction of propagation. The focal activation lasted for 8–10 beats (the initial VT phase) and then
degenerated to VF, as shown in (E) with four optical action potentials (APs; labeled 1–4) shown in the adjacent schema (From Bapat et al., 2012).
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normal EC coupling, while at the same time potently suppressing
the EADs. These findings suggest that a new class of drug
action, “gating modifiers,” as in the case of INa-L, that induce
subtle changes of the gating properties of the LTCC and Nav
channels without blocking their pores suppress EAD-mediated
VT/VFwithout adversely affecting contractility. Interestingly, the
identification roscovitine, a purine derivative (anticancer agent)
able to selectively reduce the late ICa,L without affecting the peak
ICa,L represents a turning point in the electropharmacology of
AADs (Yarotskyy and Elmslie, 2007; Yazawa and Dolmetsch,
2013; Figure 2D).
Intact Heart Models of EAD-Mediated
VT/VF via CaMKII Signaling
We and others have shown that oxidative activation of CaMKII
by hydrogen peroxide (H2O2) increases the INa-L and late ICa,L
and readily promotes EADs and triggered activity in isolated
rat and rabbit ventricular myocytes (Ward and Giles, 1997;
Song et al., 2006; Xie et al., 2009; Madhvani et al., 2015). At
tissue level however, EADs may be suppressed by source-sink
mismatches arising from cell-to-cell coupling. That is, the small
inward current which is sufficient to reverse repolarization and
cause an EAD at the isolated myocyte level will be “diluted”
into adjacent repolarizing myocytes at the tissue level (unless
they are also simultaneously primed for an EAD), thereby
preventing EAD formation. The isolated single cell vs. tissue level
vulnerability to EAD formation was investigated by examining
the arrhythmogenic effects of hydrogen peroxide (H2O2) in
Langendorff rat and rabbit hearts. Oxidative stress was shown
to readily induce EADs at the isolated myocyte level in these
two species. Consistent with the predicted suppressive effects of
well-coupled tissue on EADs, we found that oxidative stress with
H2O2 failed to induce any ventricular arrhythmias in normal
well-coupled young/adult (∼4 months old) rat and rabbit hearts
FIGURE 5 | Spontaneous initiation of ventricular tachycardia (VT)/VF in an aged rat heart exposed to 0.1 mM H2O2. (A) ECG showing the last 5 sinus
beats before the sudden onset of VT leading to VF. (B) voltage snapshots of the last beat of the VT (beat 1) and of the first 2 beats of the VF (beats 2 and 3). In each
snapshot, activation time (in ms) is shown at the bottom right with time 0 (arbitrary) coinciding with the onset of beat 1. The red color in the snapshots represents
depolarization (Dep) and the blue repolarization (Rep) as shown in (E). The yellow arrows in the snapshots represent the direction of the wavefront propagation with
double horizontal lines denoting the site of conduction block. The VT originates from a focal site at the LV base and propagates as single wavefront toward the apex
and undergoes functional conduction block at site 3. The two lateral edges of the front, however, continue to propagate laterally (snapshot, 98 ms) forming figure-eight
reentry (snapshot, 108 ms). During the second reentrant wavefront, another wavefront emerges from the apical site of the LV (snapshot, 122 ms), disrupting the
activation pattern and signaling the onset of VF. (D) 3 optical action potentials (APs; labeled 1, 2, and 3) recorded from sites identified on the heart silhouette (C). The
2 downward-pointing blue arrows indicate the direction of propagation from site 1 to site 3 with the red downward-pointing arrow showing block at site 3, followed by
retrograde activation (upward-pointing arrow). Notice the emergence of spatially discordant AP duration (APD) alternans preceding conduction block at site 3 when
the front with short APD (S) at site 1 encroaches a site (site 3) with long APD (L) (From Morita et al., 2009).
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(Figure 4A). Even a tenfold increase in the level of peroxide
failed to promote EADs in these normal hearts (Morita et al.,
2009). However, aged, 24–26 months old rat hearts, manifest
considerable heterogeneous increase in interstitial tissue fibrosis
(10–90%), with reduced cell-to-cell gap junctional couplings
via connexin43 (Cx43), H2O2 exposure consistently promoted
EADs and triggered activity leading in >90% of the aged fibrotic
hearts to VT/VF. (Figures 4B–E) Similarly, middle-aged, 3–5
years old, (normal life span 8–12 years) rabbit hearts, with
lesser rise in fibrosis (5–35%) than in aged rat hearts and
developed lesser incidence (∼50%) of EAD-mediated triggered
VF (Morita et al., 2009; Sato et al., 2009). Although other
aging-related factors may play a role in EAD-mediated VF, we
hypothesized that reduced cell-to-cell gap junctional coupling in
fibrotic aged hearts promotes oxidative EAD-related arrhythmias
by favorably altering source-sink relationships. Indeed, computer
simulation in 1, 2, and 3D cardiac tissue incorporating fibrosis
fully supported this interpretation (Xie et al., 2010; Morita et al.,
2011a). The involvement of peroxide, as a redox sensor of
CaMKII, is validated by demonstrating similar VT/VF outcomes
with more proximal oxidative signaling using acute angiotensin
II perfusion (Bapat et al., 2012) or by mimicking distal
consequences of oxidative stress, such as glycolytic inhibition
(Corretti et al., 1991), all promoting EAD-mediated VT/VF as
in the case of H2O2 (Morita et al., 2011b). Interestingly both
oxidative stress with peroxide (Pezhouman et al., 2014a) or
downstream oxidative injury with glycolytic inhibition (Ono
et al., 2007) in aged atria promote atrial EADs, tachycardia and
fibrillation (AT/AF) in aged rat atria as in aged rat ventricles.
However, it remains to be seen if block of the late inward currents
would also prevent and suppress AT/AF in other species such as
rabbit, goat, sheep and dog models of AT/AF.
ENHANCED LATE INWARD CURRENTS
PROMOTE BOTH FOCAL TRIGGERED AND
REENTRANT ARRHYTHMIAS
The EADs and the subsequent propagating triggered beats
initiate diverse forms of ventricular arrhythmias starting from
single PVCs, focal non-reentrant monomorphic or polymorphic
VT and torsade de pointes that lead to the highly arrhythmogenic
spatially discordant APD alternans causing wavebreak, reentry
and transition from VT to VF (Morita et al., 2011a,b; Bapat
FIGURE 6 | Spontaneous initiation of VF in a middle-aged rabbit exposed to 0.1 mM H2O2. (A) Six epicardial optical APs (V1–V6) recorded from sites shown
on the left silhouette of the heart. After nine focal activations arising from the base of the heart (B), the wavefront undergoes block at mid-LV anterior wall after spatially
discordant APD alternans emerges (A). The wavefront, however, continues to propagate lateral to the site of block in a clockwise direction causing a reentrant
excitation as shown in the snapshots in (B). The numbers under each snapshot is activation time starting with 0 ms (arbitrary) for beats 3 and 4 and then again for
beats 10 and 11. (C) microelectrode recording of another VF episode recorded in the same heart showing spontaneous initiation of VF by a mechanism compatible
with early afterdepolarization (EAD)-mediated triggered activity (TA) as in the aged rat hearts shown in Figure 6 (From Morita et al., 2009).
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et al., 2012; Chang et al., 2012; Pezhouman et al., 2015)
as shown in Figures 5, 6. In addition to triggered foci, the
oxidative stress may also initiate reentry by the phenomenon
of “repolarization failure” during which the AP remains in
the plateau region for a few seconds before undergoing full
repolarization (Bapat et al., 2012). Localized myocardial regions
with failed repolarization creates a considerable increase in
spatial dispersion of repolarization promoting wavebreak and
reentry (Weiss et al., 2000; Antzelevitch, 2008; Sato et al., 2009;
Bapat et al., 2012; Karagueuzian et al., 2013). Heterogeneous
increase in the late inward currents can also promote APD
dispersion via their actions on the kinetics of APD restitution.
Enhanced INa-L and late ICa,L by prolonging the APD increase
the slope of the APD restitution curve (Qu et al., 2000; Guo et al.,
2011; Morita et al., 2011a; Pezhouman et al., 2014b; Figure 7).
Increasing the slope of the APD restitution curve promotes
voltage- but not Ca-driven APD alternans (Weiss et al., 2006)
which with a critical increase in the rate of activation converts
the concordant APD alternans to the highly arrhythmogenic
spatially discordant APD alternans (out-of-phase APD alternans)
promoting unidirectional conduction block and reentry (Weiss
et al., 2006; Morita et al., 2009; Karagueuzian et al., 2013).
Selective block of the INa-L with GS-967 or selective block of
the late ICa,L with roscovitine flatten the slope of the APD
restitution curve preventing wavefront breakup and reentry
by preventing the emergence of spatially discordant APD
alternans (Pezhouman et al., 2014b, 2016; Angelini et al.,
2016; Figures 7, 8). Interestingly flattening of the slope of
the APD restitution with drugs that do not block the INa-L
also prevent wavebreak and reentry but do not prevent EAD-
mediated triggered activity (INa-L remains elevated) causing the
maintenance of VT with no transition to VF. This dynamic
scenario is confirmed with the studies with diacetyl monoxime
(DAM), a drug that flattens the slope of the APD restitution
curve without affecting the late currents (Coulombe et al.,
1990; Riccio et al., 1999). DAM decreases in a concentration-
dependent manner the amplitude of both the slow inward
calcium current and the transient outward current, accelerating
their inactivation and shifting their steady-state inactivation-
voltage relationships toward negative potentials (Coulombe
et al., 1990). In isolated-perfused swine ventricles in which
EAD-mediated triggered VT/VF is initiated by myocardial
FIGURE 7 | Suppression of aconitine-induced ventricular tachycardia/ventricular fibrillation (VT/VF) with the specific INa-L blocker, GS967(1 µM) and
reversal of its effect on washout. (A) Aconitine-induced VF, which converts to monomorphic VT 3min after arterial perfusion of GS967 (B) and to sinus rhythm
7min after GS967 (C). Washout of GS967 with drug-free Tyrode’s perfusion causes the reemergence of monomorphic VT that degenerates to VF 8min after GS967
washout (D). The reintroduction of GS967 in the perfusate suppresses the VF by first converting it to monomorphic VT and then to sinus rhythm (E). Note the marked
shortening of the action potential duration after GS967-induced conversion of the monomorphic VT to sinus rhythm despite lengthening of the cycle length (C, E)
(from Pezhouman et al., 2014b).
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FIGURE 8 | Effect of GS967 on use-dependent action potential duration (APD), action potential amplitude (APA), and APD restitution. (A) Baseline
microelectrode recordings of action potentials at two pacing cycle lengths (PCLs): 200 ms (top) and100 ms (bottom). (B) Effects of GS967 at these two PCLs, causing
2 and 7% reduction in APA and 32 and 48% reduction in APD, respectively. (C) Superimposed APs showing that GS967 causes greater shortening of APD than APA
at faster rates (use-dependent). (D) Mean percent shortening of APA and APD as a function of PCL. (E) Effect of GS967 on slope of dynamic APD restitution curves
both at baseline and after aconitine. (F) Superimposed APs at baseline, after aconitine injection just before initiation of VT/VF and after GS967 (From Pezhouman
et al., 2014b). *p < 0.01;
†
p < 0.05.
local injection of aconitine (Swissa et al., 2002) an agent
that selectively enhances the INa-L considerably (Peper and
Trautwein, 1967), the administration of DAM prevented
transition of aconitine-induced EAD-mediated triggered VT to
VF which remained maintained by a single triggered focus
maintaining a monomorphic VT (Swissa et al., 2002). The
flattening of the slope of the APD restitution curve by DAM
differs from that of GS-967 in that the latter unlike DAM by
selectively blocking the INa-L suppresses both EAD-mediated
triggered activity and reentry caused by wavebreak due to the
flattening the slope of the APD restitution resulting in the
conversion aconitine-induced VF to sinus rhythm (Pezhouman
et al., 2014b; Figures 7, 8).
SPECIFIC VS. NON-SPECIFIC BLOCK OF
DRUGS AND VT/VF
Many of the Class I AADs like mexiletine, flecainide,
and propafenone, while blocking the peak INa (Figure 1)
also manifest variable degree of block of the INa-L as
well (Antzelevitch et al., 2014). However, the potential of
proarrhythmia with these agents led to the development of more
selective blockers of INa-L, with no appreciable effect on the
peak INa (Belardinelli et al., 2013). Furthermore, Class IC drugs
like flecainide and propafenone in addition of being potent
peak INa inhibitors also inhibit ryanodine 2 (RyR2) channels
in the open-state, suppressing Ca2+ waves and preventing VT
in the congenital catecholaminergic polymorphic ventricular
tachycardia (CPVT) both in mice and humans (Hilliard et al.,
2010). Clinical studies have shown that CaMKII activation in
heart failure (Swaminathan et al., 2012) with its downstream
increases of both INa-L and late ICa-L may require the block
of both late inward currents to be effective against VT/VF
(Figure 9). Support to this contention comes from simulation
(Foteinou et al., 2015) and clinical studies that showed the need
to combine ranolazine with verapamil to effectively suppress
VT/VF in a patient with TS (LQT8) (Shah et al., 2012). While
triggered activity either by EAD and subsequent emergent of
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FIGURE 9 | Schema of positive feedback loops promoting intracellular
Na and Ca overload, CaMKII activation, and EADs during stress
induced with hydrogen peroxide, angiotensin II, and hypokalemia. The
enhanced late inward currents potentiate CaMKII activity (positive feedback
loop) by prolonging APD and promoting EADs leading to VT/VF. APD indicates
action potential duration; CaMKII, Ca-calmodulin kinase II; EAD, early
afterdepolarization.
DADs (Pezhouman et al., 2014b) remains a viable mechanism
of VT/VF, the prevailing concept of AAD therapy in patients
with healed myocardial infarction and other cardiomyopathies
however, is largely based on how to disrupt reentrant excitation
to terminate VT/VF (de Bakker et al., 1991; Pogwizd et al., 1992;
Wu et al., 1998; Nash et al., 2006). Accordingly, the strategy of
AAD is largely based (save for rare channelopathies, like CPVT)
on a drug’s ability to block ionic currents to disrupt reentrant
arrhythmias. In fact, by directly altering cardiac wavefront
conduction and refractoriness reentry may be prevented
(Rosen and Janse, 2010). With this mindset it is proposed
that Na channel blockers (i.e., Class I AAD) suppress reentry
by decreasing conduction velocity and excitability converting
unidirectional conduction block necessary for reentry formation
to bidirectional conduction block preventing reentry and VT/VF
(Karagueuzian and Chen, 2001). These expectations proved to be
not only disappointing with respect to clinical therapy of VT/VF
but also carried significant proarrhythmic risks. For example, the
outcome of CAST clinical trial indicated that inhibition of peak
Na current (Class 1C) was ineffective and even carried greater
risk of mortality (Echt et al., 1991). Similarly, the SWORD
clinical trials with d-sotalol (Class III) (Waldo et al., 1995) were
also based on the premise of preventing reentry formation this
time by increasing the cardiac refractoriness, an effect that will
eliminate (close) the excitable gap necessary for reentry causing
termination of the reentry. The results of CAST and SWORD
showed drugs with Class I and Class III actions are ineffective
in suppressing the arrhythmia following myocardial infarction
(Echt et al., 1991; Waldo et al., 1995).
New AAD Class Action (Class VI)
The current AAD classification, classically known as the Vaughan
Williams classification, needs to be refined and updated with
recent findings that attribute key arrhythmogenic role to the
pathological rises of the late inward currents. As stated by
Thireau and associates: “The VaughanWilliams classification may
no longer be best suited to the realities of new AA drug design”
(Thireau et al., 2011).
The key role played by the sustained elevation of the INa-L
and late ICa,L in the genesis of focal and reentrant VT/VF
qualify these pathological changes in ionic current kinetics bone
fide “vulnerable parameters” of arrhythmias that are selectively
targetable by small molecule drugs. In fact, the emergences of
potent and prototype specific blockers of these late currents offers
a new and effective AAD class action not considered previously.
Since a fifth class of AAD actions is already assigned to diverse
other agents (Table 1) it is suggested that the specific modifiers of
the INa-L and late ICa,L (gatingmodifiers) be assigned a sixth AAD
class action (Class VI). Prototype drugs with these class of actions
are steadily becoming available including GS-967, the mexiletine
analogs, HBRI21 & HBRI23 and roscovitine, that manifest high
selectivity against the late INa-L and the ICa,L respectively without
affecting their peaks (McKeithan et al., 2016). To distinguish
between the two inward currents, the notations of Class VINa
and Class VICa may be added to indicate specific INa-L and
late ICa,L blockers respectively. The concept of AAD therapy
based on changes in ion channel gating rather than peak current
block (i.e., gating modifiers) represents a turning point in AAD
therapy that would provide a stimulus for future research in
the field of AAD discovery that remained idle for decades
(Kamath and Mittal, 2008; Thireau et al., 2011). Here, it is fitting
to re-state the Editorial comments entitled “Rational strategy
to stop arrhythmias...” made our group’s findings (Madhvani
et al., 2015) on the role of the late ICa,L in the genesis of
EADs:
“...Existing strategies for developing antiarrhythmic drugs have
largely failed, and so new, innovative approaches as described by
Madhvani et al. 2015 need to be aggressively pursued and tested”
(Markandeya and Kamp, 2015).
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